[Experience with the use of midantan for treatment and prevention of the neuroleptic syndrome].
D000328:Adult; D000547:Amantadine / Q000627:therapeutic use*; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000009:adverse effects; D002389:Catatonia / Q000188:drug therapy; D002746:Chlorpromazine / Q000009:adverse effects; D005152:Facial Muscles; D005260:Female; D006801:Humans; D006948:Hyperkinesis / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000139:chemically induced / Q000188:drug therapy* / Q000517:prevention & control; D009120:Muscle Cramp / Q000139:chemically induced; D009333:Neck; D010276:Parasympatholytics / Q000627:therapeutic use; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000188:drug therapy* / Q000517:prevention & control; D010608:Pharyngeal Diseases / Q000188:drug therapy; D012131:Respiratory Insufficiency / Q000188:drug therapy; D012559:Schizophrenia / Q000188:drug therapy; D012563:Schizophrenia, Paranoid / Q000188:drug therapy; D013064:Speech Disorders / Q000188:drug therapy; D013610:Tachycardia / Q000188:drug therapy; D014149:Tranquilizing Agents / Q000009:adverse effects*
D000978:Antiparkinson Agents; D014150:Antipsychotic Agents; D010276:Parasympatholytics; D014149:Tranquilizing Agents; D000547:Amantadine; D002746:Chlorpromazine
Opyt primeneniia midantana dlia lecheniia i profilsktiki neĭrolepticheskogo sindroma.